HeartFlow, Inc.

HeartFlow, Inc. applies artificial intelligence and computational simulation to coronary artery disease (CAD). From standard coronary CT angiography (CCTA) images, the company generates detailed 3D models of the heart to support clinicians in diagnosing, treating and managing CAD. Its technical work spans medical imaging, computer vision, 3D modelling, computational fluid dynamics and blood-flow simulation, plaque quantification and cardiac CT analysis.

The company's products are organised around the CCTA pathway. Roadmap Analysis visualises and quantifies coronary narrowings; FFRCT Analysis uses personalised 3D simulations to assess the effect of blockages on blood flow; and Plaque Analysis characterises and quantifies coronary atherosclerosis. These sit within HeartFlow One, a non-invasive coronary care platform that provides patient insights across the guideline-directed CCTA pathway.

HeartFlow reports that more than 600,000 patients have been treated using its technology and that over 1,800 institutions have adopted it. The underlying approach is supported by more than 625 peer-reviewed publications and is referenced in ACC/AHA clinical guidelines. Coverage through Medicare and major commercial insurers extends to 99.5% of U.S. lives.

The company is publicly traded on Nasdaq under the ticker HTFL. It is headquartered in San Francisco, California, and operates in the United States, Europe and Japan. Its stated objective is to transform CAD from the leading cause of death into a disease that can be managed for life.